HOME >> MEDICINE >> NEWS
New protease inhibitor held HIV at undetectable levels for four years

A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir/ritonavir (Kaletra) suppressed HIV to undetectable levels and was well tolerated through four years of treatment in patients who had not previously received antiretroviral therapy.

To date in the Kaletra study, none of the patients has developed resistance to Kaletra or other protease inhibitors. Kaletra is thus far the only protease inhibitor for which resistance has not been observed in patients receiving it as an initial therapy.

Robert L. Murphy, M.D., professor of medicine at the Feinberg School and director of HIV/AIDS clinical research at Northwestern University, presented results of the study today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.

"Maintaining antiviral suppression to undetectable levels over the long term is crucial to patients' success," Murphy said.

"Drugs such as Kaletra, which have demonstrated high rates of viral suppression over several years, remain important options for initial therapy. Viral suppression helps prolong the time to development of resistance, which is an important cause of treatment failure," Murphy said.

In this ongoing phase II study, 100 patients who had not previously received antiretroviral therapy were given one of three doses of Kaletra in addition to the nucleoside analogues stavudine and lamivudine.

After 48 weeks, therapy for all patients was converted to the same dose of Kaletra with stavudine and lamivudine. Of the original group of patients, 72 remained in the study through four years; seven of the 28 patients who discontinued therapy did so because of adverse events attributed to Kaletra. All 72 patients maintained an undetectable HIV viral load of less than 400 copies per milliliter, and their CD4 counts increased consistently from the beginning of the study over the four-year period (mean increase of 416 cells per cubic millimeter).

Ka
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
27-Sep-2002


Page: 1 2

Related medicine news :

1. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
2. HIV-1 protease inhibitors: Effective against malaria?
3. FDA approves new HIV protease inhibitor, Lexiva (TM)
4. Pharmacokinetic data presented at ICAAC on investigational HIV protease inhibitor 433908 (908)
5. Molecules inhibit HIV protease, could lead to new line of attack against AIDS
6. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave
7. Two studies compare triple nucleoside therapy Ziagen® + Combivir® with protease inhibitorplus Combivir® regimens in therapy-naive patients
8. COX-2 inhibitors associated with blood pressure elevation
9. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
10. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
11. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2018)... (PRWEB) , ... December 08, 2018 , ... ... whiskerDocs, the leading provider of telehealth support for pet parents, has become an ... companion animals. , “By supporting the advancement of human-animal bond research, ...
(Date:12/6/2018)... ... December 06, 2018 , ... Pulse8’s Senior ... of Blue Cross and Blue Shield of Kansas City, will present on “Boosting ... 2018 at 2:15pm PT at the Fairmont Grand Del Mar in San Diego, ...
(Date:12/5/2018)... ... , ... Body by Ravi Plastic Surgery and Aesthetics is ... offer the BodyTitePRO treatment. Dr. Ravi Somayazula , practice founder, has dedicated ... techniques to improve the face, breast and body. Together with his partner, Swapna ...
(Date:12/5/2018)... , ... December 05, 2018 , ... ... Initiative leadership training on January 26 at North Monroe Baptist Church, 210 Finks ... 2019 trainings, part of the agency’s effort to educate and equip faith leaders ...
(Date:12/5/2018)... SAN DIEGO (PRWEB) , ... December 05, 2018 , ... ... on the field of nursing. Available starting today and on a weekly rolling basis ... Doctor of Nursing Practice in Executive Leadership (DNP) will prepare degree candidates ...
Breaking Medicine News(10 mins):
(Date:12/5/2018)... Calif. (PRWEB) , ... December 05, 2018 , ... Smile ... year in a row moving from the 43rd to 25th position on the ... Choice Awards program, now in its 11th year, relies solely on the input of ...
(Date:12/5/2018)... ... December 05, 2018 , ... WHO: The Institute for ... Livestreaming of four keynote addresses and five spotlight sessions taking place during ... for session descriptions and speakers) , WHEN: Beginning Tuesday, December 11 ( full schedule ...
(Date:12/5/2018)... ... December 04, 2018 , ... The inaugural Steven Schroeder Award ... of Virginia Mason Health System in Seattle, Washington, at The Leapfrog Group ’s ... Costs of Care , a leading non-profit dedicated to curating and disseminating insights ...
Breaking Medicine Technology:
Cached News: